TD Cowen initiated coverage of Geron with a Buy rating and $10 price target. The firm says imetelstat is disease-modifying with the most durable transfusion independence it has seen in lower risk myelodysplastic syndromes. The drug also works broadly and can address currently underserved patient populations upon potential approval in June, which is as likely based on the 12-2 FDA panel vote, the analyst tells investors in a research note. Further, success in high-risk myelofibrosis could double imetelstat’s opportunity, contends TD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GERN:
- Geron prices $150M offering of common stock and warrants at $3.00 per share
- Biotech Alert: Searches spiking for these stocks today
- Largest borrow rate increases among liquid names
- Geron price target raised to $5 from $4 at Needham
- Geron reports FDA advisors vote in favor of benefit/risk of imetelstat
